ARKG ARK Genomic Revolution ETF
- 25.115
- +1.285+5.39%
JPMorgan Updates Its U.S. Analyst Focus List – Adds TPR, ALRM, REG
Pfizer Meets Amyloidosis Rival as BridgeBio Wins FDA Nod for Attruby
Goldman's Hedge Fund VIP List: AMZN, VST, CRM, BABA, and More
Recursion Pharmaceuticals Analyst Ratings
Trump Media Saw the Largest Increase in Short Interest in October
AI software stocks make a big comeback! Applovin's annual growth is 7 times that of Nvidia, which other stocks are worth paying attention to?
Since the end of last year, benefiting from the improvement of large model capabilities and the support of ai infrastructure, ai has gradually driven the commercialization of software on the software side, empowering enterprises to achieve performance growth. After the successive boom in ai hardware, the global market's attention is gradually shifting to software. What signal is the capital sensing?
JPMorgan's 'Analyst Focus List' – Growth, Income, Value, Short Ideas
Baird Maintains Outperform on Twist Bioscience, Raises Price Target to $48
Twist Bioscience Analyst Ratings
12 Health Care Stocks Moving In Monday's Pre-Market Session
Analyst Expectations For Natera's Future
Natera Analyst Ratings
Twist Bioscience's Q4 Earnings And Q1 Guidance Surpass Expectations, Stock Jumps
Veracyte Analyst Ratings
Twist Bioscience Posts Upbeat Results, Joins Tesla, Amylyx Pharmaceuticals, Regenxbio And Other Big Stocks Moving Higher On Monday
Top Wall Street Forecasters Revamp Twist Bioscience Price Expectations Ahead Of Q4 Earnings
Twist Bioscience Q4 2024 GAAP EPS $(0.59) Beats $(0.70) Estimate, Sales $84.71M Beat $82.20M Estimate
Earnings Scheduled For November 18, 2024
Earnings Week Ahead: NVDA, WMT, SNOW, TGT, BIDU, NIO, ZIM, and More
What kind of company is Natera, the largest hold positions of Drew Miller?
Currently, there is a lack of precision in adjuvant therapy plans after tumor (MRD) surgery, while MRD testing can detect molecular abnormalities originating from the tumor, enabling early detection of cancer recurrence and guiding precise postoperative treatment. Huayuan Securities believes that natera's MRD testing business has significant competitive advantages, and its launched Signatera product is expected to become the core driving force behind the company's rapid performance improvement.